Bank of New York Mellon
PMVP icon

Bank of New York Mellon’s PMV Pharmaceuticals PMVP Stock Holding History

Bank of New York Mellon’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-117,101
Closed -$199K – 4231
2024
Q1 		$199K Sell
117,101
-8,386
-7% -$15.7K ﹤0.01% 3936
2023
Q4 		$389K Buy
125,487
+997
+0.8% +$2.64K ﹤0.01% 3694
2023
Q3 		$764K Sell
124,490
-248
-0.2% -$1.71K ﹤0.01% 3328
2023
Q2 		$781K Buy
124,738
+2,218
+2% +$11.6K ﹤0.01% 3349
2023
Q1 		$584K Sell
122,520
-279
-0.2% -$1.96K ﹤0.01% 3415
2022
Q4 		$1.07M Buy
122,799
+346
+0.3% +$3.69K ﹤0.01% 3161
2022
Q3 		$1.46M Buy
122,453
+17,776
+17% +$257K ﹤0.01% 3026
2022
Q2 		$1.49M Buy
104,677
+24,528
+31% +$357K ﹤0.01% 2997
2022
Q1 		$1.67M Sell
80,149
-214
-0.3% -$3.77K ﹤0.01% 3034
2021
Q4 		$1.86M Buy
80,363
+2,987
+4% +$72.2K ﹤0.01% 3037
2021
Q3 		$2.31M Buy
77,376
+11,666
+18% +$372K ﹤0.01% 2902
2021
Q2 		$2.24M Buy
65,710
+25,297
+63% +$845K ﹤0.01% 2913
2021
Q1 		$1.33M Sell
40,413
-881
-2% -$34.7K ﹤0.01% 3173
2020
Q4 		$2.54M Buy
+41,294
New +$1.62M ﹤0.01% 2702

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of New York Mellon's PMVP Position: Q2 2024 in Review

Bank of New York Mellon sold out of PMV Pharmaceuticals (PMVP) in Q2 2024, closing a stake of 117,101 shares — an estimated $199K sold.

Bank of New York Mellon first reported a position in PMVP in Q4 2020 and held it in 14 quarters. The position peaked at $2.54M in Q4 2020. 93 funds tracked by Wall St. Rank hold PMVP as of Q2 2024.

  • Bank of New York Mellon reported no remaining PMV Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 117,101 PMV Pharmaceuticals shares in Q2 2024, an estimated $199K.
  • Bank of New York Mellon first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • Bank of New York Mellon's PMV Pharmaceuticals position peaked at $2.54M in Q4 2020.
  • 93 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.